Pioneering mRNA Cell Therapy for
Pioneering RNA Cell Therapy for autoimmune diseases
Our Commitment to our Patients
We are committed to developing potent yet safer cell therapies for patients with autoimmune diseases.
Our therapeutic candidates
We are conducting clinical trials in patients with autoimmune diseases.
We are an integrated team of physicians and scientists working to develop the safest, most effective mRNA cell therapies for our patients.
Stay up to date on Cartesian
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024…